Validation of a novel antiviral drug candidate against influenza

Project description

Novel drugs stop influenza replication

Fields of science

• medical and health sciences › basic medicine › pharmacology and pharmacy › drug discovery
• natural sciences › biological sciences › microbiology › virology
• medical and health sciences › health sciences › public health › epidemiology › pandemics
• medical and health sciences › health sciences › infectious diseases › RNA viruses › influenza
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs › antivirals

Programme(s)

• H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme

Topic(s)

• ERC-2019-POC - ERC Proof of Concept Grant

Call for proposal

ERC-2019-PoC

See other projects for this call

Funding Scheme

ERC-POC-LS - ERC Proof of Concept Lump Sum Pilot

Host institution

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

Net EU contribution

€ 139 081,00

Address

Rue De Tolbiac 101
75654 Paris
France

Region

Ile-de-France › Ile-de-France › Paris

Activity type

Research Organisations

Links

Other funding

No data

Beneficiaries (2)

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

Net EU contribution

€ 139 081,00

Address

Rue De Tolbiac 101
75654 Paris

Region

Ile-de-France › Ile-de-France › Paris

Activity type

Research Organisations

Links

Other funding

No data

CNRS INNOVATION

France

Net EU contribution

€ 10 919,00

Address

79 Avenue Edouard Vaillant Le Quintet Bat D
92100 Boulogne-billancourt

Region

Ile-de-France › Ile-de-France › Hauts-de-Seine

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

Other funding

No data